TITLE:
Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes
AUTHORS:
Bill E. Cham
KEYWORDS:
Periocular Skin Cancers; CuradermBEC5; Apoptosis; Solamargine; Basal Cell Carcinoma; Squamous Cell Carcinoma; Cosmesis; Solanum
JOURNAL NAME:
International Journal of Clinical Medicine,
Vol.4 No.5,
May
16,
2013
ABSTRACT: Approximately
5 to 10 percent of all skin cancers occur in the periocular region. Basal cell
carcinoma is the most frequent malignant periocular
tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and
malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause
disfigurement with destruction of soft conjunctival
tissue. Many therapeutic methods have been recommended to combat
the morbidity and mortality associated with these lesions. Excisions with
frozen-section control or Mohs micrographic surgery are regarded as the
gold-standard treatments for periocular basal cell and squamous cell
carcinomas. However, these treatment modalities have various limitations and
reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a
cream formulation CuradermBEC5 are specific, effective and safe
treatments for nonmelanoma skin cancers with excellent
cosmesis. The antineoplastic mode of action is by apoptosis. In this review it
is shown that CuradermBEC5 also treats periocular basal cell
carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no
reconstructive surgery is required.